Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial

References

• Ludwig H, Durie BG, Bolejack V, . Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 2008;111:4039–4047.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Debes-Marun CS, Picken EB, . The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102:2562–2567.
   PubMed Web of Science ®Google Scholar
• Smadja NV, Leroux D, Soulier J, . Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003;38:234–239.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333–6338.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Santana-Davila R, Van Wier SA, . Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006;20:807–813.
   PubMed Web of Science ®Google Scholar
• Carrasco DR, Tonon G, Huang Y, . High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313–325.
   PubMed Web of Science ®Google Scholar
• Moreau P, Facon T, Leleu X, . Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002;100:1579–1583.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Attal M, Moreau P, . Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–3495.
   PubMed Web of Science ®Google Scholar
• Gutierrez NC, Castellanos MV, Martin ML, . Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143–150.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi X, Trieu Y, . Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. Br J Haematol 2006;135:486–491.
   PubMed Web of Science ®Google Scholar
• Hanamura I, Stewart JP, Huang Y, . Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006;108:1724–1732.
   PubMed Web of Science ®Google Scholar
• Boyd KD, Ross FM, Tapper WJ, . Defining high risk myeloma using co-segregating FISH variables; results of MRC Myeloma IX. Blood 2010;116(Suppl. 1): Abstract 1907.
   Google Scholar
• Hajek R, Spicka I, Scudla V, . Consolidation therapy based on conventional chemotherapy and corticoids do not provide therapeutic advantage for newly diagnosed patients after autologous transplantation. Blood 2007;110(Suppl. 1): Abstract 531.
   Google Scholar
• Nemec P, Zemanova Z, Greslikova H, . Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant 2010;16:548–554.
   PubMed Web of Science ®Google Scholar
• Ross FM, Avet-Loiseau H, Drach J, .; on behalf of the European Myeloma Network FISH Working Party. European Myeloma Network recommendations for FISH in myeloma. Haematologica 2007;92(Suppl. 2):100–101.
   Web of Science ®Google Scholar
• Avet-Loiseau H, Leleu X, Roussel M, . Deletion of the 17p chromosomal region is associated with a very poor outcome in multiple myeloma independently of the type of treatment. Blood 2009;114:721–722.
   Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, . International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Blood E, Rue M, . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569–4575.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Bertsch U, . Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010;95:1150–1157.
   PubMed Web of Science ®Google Scholar
• Greslikova H, Zaoralova R, Filkova H, . Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation. Neoplasma 2010;57:111–117.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005;10(Suppl. 1):117–126.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Van Wier SA, Chng WJ, . Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006;20:2034–2040.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Zhan F, Burington BE, . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–2284.
   PubMed Web of Science ®Google Scholar
• Keats JJ, Maxwell CA, Taylor BJ, . Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood 2005;105:4060–4069.
   PubMed Web of Science ®Google Scholar
• Santra M, Zhan F, Tian E, . A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003;101:2374–2376.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Oken MM, Harrington D, . Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001;15:981–986.
   PubMed Web of Science ®Google Scholar
• Avet-Louseau H, Daviet A, Sauner S, . Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000;111:1116–1117.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Tian E, Sawyer J, . High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 2000;96:1505–1511.
   PubMed Web of Science ®Google Scholar
• Zojer N, Konigsberg R, Ackermann J, . Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925–1930.
   PubMed Web of Science ®Google Scholar
• Chiecchio L, Protheroe RK, Ibrahim AH, . Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006;20:1610–1617.
   PubMed Web of Science ®Google Scholar
• Shaughnessy J Jr, Tian E, Sawyer J, . Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003;120:44–52.
   PubMed Web of Science ®Google Scholar
• Drach J, Ackermann J, Fritz E, . Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998;92:802–809.
   PubMed Web of Science ®Google Scholar
• Xiong W, Wu X, Starnes S, . An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008;112:4235–4246.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi C, Yi QL, . p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005;105:358–360.
   PubMed Web of Science ®Google Scholar
• Reece D, Song KW, Fu T, . Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009;114:522–525.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, . Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–2840.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Kumar S, Fonseca R, . Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009;114:518–521.
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Mansoor A, Lategan JC, . Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. Blood 2006;108(Suppl. 1): Abstract 3557.
   Google Scholar
• Jagannath S, Richardson PG, Sonneveld P, . Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151–157.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, . Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977–2981.
   PubMed Web of Science ®Google Scholar
• Sagaster V, Ludwig H, Kaufmann H, . Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21:164–168.
   PubMed Web of Science ®Google Scholar